Müllerin solut ja tauriini

Müllerin solut ja tauriini

Ensinnäkin Müllerin solu tarvitsee cystiiniä, jonka se siirtää solun sisään.

 Milloin on cystiinivajetta seerumissa, josta se koettaa saada sitä?

 ATP:tä synteesiin tulee toimivasta sitruunahappokierrosta.

ESIM:

Alamainitaan, että AD taudissa havaitaan metabolista häiriötä seuraavaan tapaan ja tässä on katsottujen molekyylien joukossa myös Müllerin solujen tarvitsema cystiini-muoto, dimeeri cysteiini-aminohaposta.

J Pharm Biomed Anal. 2015 Mar 25;107:75-81. doi: 10.1016/j.jpba.2014.10.010. Epub 2014 Dec 13. Metabolite profiling for the identification of altered metabolic pathways in Alzheimer's disease.

González-Domínguez R¹, García-Barrera T², Gómez-Ariza JL³.

Author information

Abstract

Gas chromatography coupled to mass spectrometry is the most frequent tool for metabolomic profiling of low molecular weight metabolites. Its suitability in health survey is beyond doubt, given that primary metabolites involved in central pathways of metabolism are usually altered in diseases. The objective of this work is to investigate metabolic differences in serum between Alzheimer's disease patients and healthy controls in order to elucidate pathological mechanisms underlying to disease. Alterations in levels of 23 metabolites were detected, including
increased
lactic acid, α-ketoglutarate, isocitric acid, glucose, oleic acid, adenosine and cholesterol, as well as decreased
urea, valine, aspartic acid, pyroglutamate, glutamine, phenylalanine, asparagine, ornithine, pipecolic acid, histidine, tyrosine, palmitic and uric acid, tryptophan, stearic acid and cystine.



Metabolic pathway analysis revealed the involvement of multiple affected pathways, such as
energy deficiencies, oxidative stress, hyperammonemia, and others.
Moreover, it is noteworthy that some of these compounds have not been previously described in AD research, such as α-ketoglutarate, isocitrate pipecolic acid, pyroglutamate and adenosine, confirming the potential of this metabolomic approach in the search of novel potential markers for early detection of Alzheimer's disease.
Copyright © 2014 Elsevier B.V. All rights reserved.

KEYWORDS:

Alzheimer's disease; Gas chromatography mass spectrometry; Metabolomic profiling; Pathology